Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q1 FY21 results · Apr–Jun 2020

Sun Pharmaceutical Industries reported revenue from operations of ₹7,585.25 crore (down 9.4% from Q1 FY20) and net loss of ₹2,426.23 crore for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	7,585.25	8,374.36	−9.4%	8,184.94	−7.3%
Other income	153.79	213.02	−27.8%	102.23	+50.4%
Total income	7,739.04	8,587.38	−9.9%	8,287.17	−6.6%
Profit before share of associates & JVs and tax	(2,183.90)	1,647.44	Turned loss	577.44	Turned loss
Share of profit/(loss) of associates & JVs	3.58	(4.73)		(1.59)
Net profit for the period	(2,426.23)	1,496.65	Turned loss	492.76	Turned loss
Attributable to shareholders of the company	(1,655.60)	1,387.48	Turned loss	399.84	Turned loss
EPS, basic (₹)	(6.90)	5.78	Turned loss	1.67	Turned loss
Net margin (%)	-32.0	17.9		6.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	2,963.04	3,309.01	−10.5%	2,836.08	+4.5%
Other income	21.19	18.58	+14.0%	1,218.65	−98.3%
Total income	2,984.23	3,327.59	−10.3%	4,054.73	−26.4%
Profit before tax	531.52	768.14	−30.8%	1,167.22	−54.5%
Net profit for the period	531.95	763.37	−30.3%	1,155.85	−54.0%
EPS, basic (₹)	2.22	3.18	−30.2%	4.82	−53.9%
Net margin (%)	18.0	23.1		40.8

Consolidated

Filed with BSE: 01 Aug 2020, 13:26 IST
Board meeting: 31 Jul 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 01 Aug 2020, 13:26 IST
Board meeting: 31 Jul 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE